<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625855</url>
  </required_header>
  <id_info>
    <org_study_id>SPR994-106</org_study_id>
    <nct_id>NCT04625855</nct_id>
  </id_info>
  <brief_title>Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spero Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spero Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the absorption, metabolism, and excretion of&#xD;
      [14C]-TBPM-PI-HBr and to characterize and determine the metabolites present in plasma, urine,&#xD;
      and where possible, feces in healthy male subjects following a single oral administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">October 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-Center, Open-Label, Non-Randomized, Phase 1 Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open-Label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of Tebipenem (TBPM) will be determined following administration of [14C]-TBPM-PI-HBr to healthy male subjects</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The primary PK outcome endpoints following oral administration of [14C]-TBPM-PI-HBr will be derived for TBPM in plasma (calculated from whole blood concentrations) based on the concentration-time profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity will be determined following administration of [14C]-TBPM-PI-HBr to healthy male subjects</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The primary PK outcome endpoints following oral administration of [14C]-TBPM-PI-HBr will be derived for total radioactivity in whole blood and plasma based on the total radioactivity concentration-time profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite profiling and chemical structuring of metabolites in plasma, urine, and, where possible, feces will be determined after a single oral dose of [14C]-TBPM-PI-HBr</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The secondary metabolite outcome endpoints will be derived:&#xD;
metabolic profile of TBPM-PI-HBr&#xD;
metabolic profile of TBPM-PI-HBr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite profiling and chemical structuring of metabolites in plasma, urine, and, where possible, feces will be determined after a single oral dose of [14C]-TBPM-PI-HBr</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The secondary metabolite outcome endpoints will be derived:&#xD;
• identification of the structure of TBPM-PI-HBr metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of a single oral dose of [14C]-TBPM-PI-HBr when administered to healthy male subjects.</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The secondary safety outcome measures for this study are as follows:&#xD;
• incidence and severity of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of a single oral dose of [14C]-TBPM-PI-HBr when administered to healthy male subjects.</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The secondary safety outcome measures for this study are as follows:&#xD;
•incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation, and urinalysis test results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TBPM-PI-HBr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBPM-PI-HBr</intervention_name>
    <description>TBPM-PI-HBr (3 x 200 mg tablets) once</description>
    <arm_group_label>TBPM-PI-HBr</arm_group_label>
    <other_name>TBPM-PI-HBr oral capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Healthy adult males, of any race, between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a total body weight&#xD;
             between 50 and 100 kg, inclusive at Screening.&#xD;
&#xD;
          -  Willing and able to provide written informed consent and comply with all study&#xD;
             assessments, restrictions, and adhere to the protocol schedule.&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, or abnormalities in&#xD;
             physical examination, laboratory variables, vital signs or ECG at the time of&#xD;
             screening and Check-in, as deemed by the Investigator (or designee).&#xD;
&#xD;
          -  Have suitable venous access for repeated blood sampling.&#xD;
&#xD;
          -  History of a minimum of 1 bowel movement per day.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History or suspicion of routine or chronic drug or alcohol abuse or dependence within&#xD;
             2 years prior to Check-in.&#xD;
&#xD;
          -  Use of tobacco, nicotine, or nicotine-replacement products within 30 days prior to&#xD;
             Check-in or planned use during the study.&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
          -  Use/receipt of any prescription or nonprescription medication, herbal products,&#xD;
             vitamins or vaccines within 14 days (or 5 half-lives whichever is longer) prior to&#xD;
             Check-in, without prior approval from the Medical Monitor.&#xD;
&#xD;
          -  Donation of more than 500 mL of blood or plasma within 56 days prior to Check-in, or&#xD;
             receipt of a blood transfusion within 1 year prior to Check-in.&#xD;
&#xD;
          -  Receipt of any other investigational product or participation in another&#xD;
             investigational clinical study that included drug treatment within 30 days, or 5 times&#xD;
             the t1/2 of the investigational drug, whichever is longer.&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating TBPM-PI-HBr, and have previously received TBPM-PI-HBr.&#xD;
&#xD;
          -  Subjects with exposure to significant diagnostic or therapeutic radiation (e.g.,&#xD;
             serial X-ray, computed tomography scan, barium meal) or current employment in a job&#xD;
             requiring radiation exposure monitoring within 12 months prior to Check-in.&#xD;
&#xD;
          -  Subjects who have participated in a radiolabeled drug study where exposures are known&#xD;
             to the Investigator within the previous 3 months prior to admission to the clinic for&#xD;
             this study or participated in a radiolabeled drug study where exposures are not known&#xD;
             to the Investigator within the previous 6 months prior to admission to the clinic for&#xD;
             this study. The total 12-month exposure from this study and a maximum of 3 other&#xD;
             previous radiolabeled studies within 3 to 12 months prior to this study will be within&#xD;
             the CFR recommended levels considered safe, per United States (US) Title 21 CFR 361.1.&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator (or designee), should not participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy adult males, of any race</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Mirkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>TBPM-PI-HBr</keyword>
  <keyword>tebipenem</keyword>
  <keyword>absorption</keyword>
  <keyword>metabolism</keyword>
  <keyword>excretion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

